Moderna's full pipeline may fuel long-term growth.
Continue » Moderna's shares could soar as it advances its mRNA platform. Compared to older vaccines, those of the mRNA ...
The COVID-19 vaccine boom made fortunes almost overnight—and destroyed them just as fast. Moderna (NASDAQ: MRNA) has fallen 58.2% over five years. BioNTech (NASDAQ: BNTX) is down 10.9% over the same ...
Zacks Investment Research on MSN
Moderna (MRNA) falls more steeply than broader market: What investors need to know
Moderna (MRNA) ended the recent trading session at $49.56, demonstrating a -7.49% change from the preceding day's closing ...
Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an ...
U.S. large-cap healthcare stocks have delivered modest year-to-date gains in 2026, holding steady into March amid its ...
Targets readouts from nine ongoing Phase 2 and Phase 3 clinical studies in its oncology pipeline, including three Phase 3 programs for intismeran autogene Further improves 2026 and 2027 expected GAAP ...
They aren't just "pandemic stocks." ...
Two stocks are standing out in premarket trading this Wednesday morning. Moderna (Nasdaq: MRNA) is up 8.9% and Ross Stores (Nasdaq: ROSS) is up 6.6% as of 8:00 AM ET, each moving on a distinct ...
With a $140 million investment, Moderna will bring its drug product manufacturing to the United States, joining a parade of drugmakers looking to strengthen their supply chains and reduce exposure to ...
Biotech giant Moderna announced it will lay off 10% of its workforce in a move CEO Stéphane Bancel called “a difficult decision but necessary step forward,” in an internal memo sent to employees on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results